REFERENCES
- Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. August 30,2002. http://www.hivatis.org
- Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency vi-rus type 1 in women treated with zidovudine. N Engl J Med. 1999;341:385–393.
- The European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS. 1999;13:1377–1385.
- Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 trans-mission. J Acquir Immune Defic Syndr. In press.
- Acosta EP, Zorrilla C, Van Dyke R, et al. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials. 2001;2: 460–465.
- Vithayasai V, Moyle GJ, Supajatura V, et al. Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optional lamivudine in pregnancy and prevention of vertical HIV transmission. J Acquir Immune Defic. 2002;30:410–412.
- Hayashi S, Beckerman K, Homma M, Kosel BW, Aweeka FT. Pharmacokinetics of indinavir in HIV-positive pregnant women. AIDS. 2000;14:1061–1062.
- López-Cortés LF, Ruiz-Valderas R, Viciana P, et al. Once-daily saquinavir-sgc plus low-dose ritonavir (1200/100 mg) in combination with efavirenz: pharmacokinetics and effi-cacy in HIV-infected patients with prior antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;32:40–242.
- Cardiello PG, Van Heeswijk RP, Hassink EA, et al. Simpli-fying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study. J Acquir Immune Defic Syndr. 2002;29:464–470.
- Montaner JSG, Saag M, Schwart R. Pharmacokinetic and safety evaluations of a once daily regimen of saquinavir soft gel capsules (SQV) in HIV-infected antiretroviral-naive patients. Antiviral Ther. 2001;6:S43.
- Gieschke R, Fotteler B, Buss N, Steiner JL. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clin Pharmacokinet 1999;37(1):75–86.
- Kilby JM, et al. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother. 2000;44:2672–2678.
- Schapiro JM, Winters MA, Stewart F, Bradley E, Norris J, Kozel M, Merigan T. The effect of high-dose saquinavir on viral load and CD4 T-cell counts in HIV-infected patients. Ann Intern Med. 1996;124:1039–1050.
- Kurowski M, Sternfeld T, Hill A, Moecklinghohff C. Com-parative pharmacokinetics and short-term safety of twice daily Fortovase/Ritonavir and Invirase/Ritonavir. In: Pro-gram and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; 2002; Seattle, WA. Abstract #432–w.
- Meaden ER, Hoggard PG, Newton P, et al. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J Antimicrob Chemother. 2002;50:583–588.